Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates

Clinical Immunology

Volumn 109, Issue 1, 2003, Pages 64-71

  Verthelyi, Daniela ^a   Klinman, Dennis M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Allergies; Cancer; CpG ODN; Human; Immunoprotection; Innate immunity; Primates; Safety; Vaccines

Indexed keywords

ALPHA INTERFERON; D TYPE OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; K TYPE OLIGODEOXYNUCLEOTIDE; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ALLERGY; ANIMAL CELL; ARTICLE; ASTHMA; CANCER; CHILL; CONTROLLED STUDY; CPG ISLAND; FEVER; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOREGULATION; INFECTION; INFLUENZA; NATURAL KILLER CELL; NONHUMAN; PRIMATE; PRIORITY JOURNAL;

EID: 0142153984     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6616(03)00202-X     Document Type: Article

References (72)

1. Yamamoto S., Yamamoto T., Shimada S., Kuramoto E., Yano O., Kataoka T., Tokunaga T. DNA from bacteria, but not vertebrates, induces interferons, activate NK cells and inhibits tumor growth. Microbiol. Immunol. 36:1992;983-997.
2. Messina J.P., Gilkeson G.S., Pisetsky D.S. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J. Immunol. 147:1991;1759-1764.
3. Krieg A.M., Yi A., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-548.
4. Sparwasser T., Koch E., Vabulas R.M., Heeg K., Lipford G.B., Ellwart J.W., Wager H. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 28:1998;2045-2054.
5. Klinman D.M., Yi A., Beaucage S.L., Conover J., Krieg A.M. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFNg. Proc. Natl. Acad. Sci. USA. 93:1996;2879-2883.
6. Yamamoto S., Yamamoto T., Katoaka T., Kuramoto E., Yano O., Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J. Immunol. 148:1992;4072-4076.
7. Klinman D.M., Barnhart K.M., Conover J. CpG motifs as immune adjuvants. Vaccine. 17:1999;19-25.
8. Sur S., Wild J.S., Choudhury B.K., Alam R., Sur N., Klinman D.M. Long-term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J. Immunol. 162:1999;6284-6291.
9. Elkins K.L., Rhinehart-Jones T.R., Stibitz S., Conover J.S., Klinman D.M. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 162:1999;2291-2298.
10. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA. 94:1997;10833-10837.
11. Bauer M., Heeg K., Wagner H., Lipford G.B. DNA activates human immune cells through a CpG sequence-dependent manner. Immunology. 97:1999;699-705.
12. Hartmann G., Krieg A.M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164:2000;944-952.
13. Verthelyi D., Ishii K.J., Gursel M., Takeshita F., Klinman D.M. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J. Immunol. 166:2001;2372-2377.
14. Roman M., Martin-Orozco E., Goodman J.S., Nguyen M., Sato Y., Ronaghy A., Kornbluth R.S., Richman D.D., Carson D.A., Raz E. Immunostimulatory DNA sequences function as T helper-1 promoting adjuvants. Nature Med. 3:1997;849-854.
15. Hartmann G., Weeratna R.D., Ballas Z.K., Payette P., Blackwell S., Suparto I., Rasmussen W.L., Waldshmidt M., Sajuthi D., Purcell R.H., Davis H.L., Krieg A.M. Delineation of a CpG phosphorothioate oligodeoxinucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164:2000;1617-1624.
16. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:2002;709-760.
17. Branda R.F., Moore A.L., Lafayette A.R., Mathews L., Hong R., Zon G., Brown T., McCormack J.J. Amplification of antibody production by phosphorothioate oligodeoxynucleotides. J. Lab. Clin. Med. 128:1996;329-338.
18. Krug A., Rothenfusser S., Hornung V., Jahrsdorfer B., Blackwell S., Ballas Z.K., Endres S., Krieg A.M., Hartmann G. Identification of CpG oligonucleotide sequences with high induction of IFNa/b in plasmacytoid dendritic cells. Eur. J. Immunol. 31:2001;2154-2163.
19. Dalpke A.H., Zimmermann S., Albrecht I., Heeg K. Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology. 106:2002;102-112.
20. Gursel M., Verthelyi D., Gursel I., Ishii K.J., Klinman D.M. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J. Leukocyte Biol. 71:2002;813-820.
21. Hemmi H., Takeuchi O., Kawai T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A Toll-like receptor recognizes bacterial DNA. Nature. 408:2000;740-745.
22. Takeshita F., Leifer C.A., Gursel I., Ishii K., Takeshita S., Gursel M., Klinman D.M. Cutting Edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 167:2001;3555-3558.
23. Bauer S., Kirschning C.J., Hacker H., Redecke V., Hausmann S., Akira S., Wagner H., Lipford G.B. Human TLR9 confers responsiveness to bacterial DNA via species specific CpG motif recognition. Proc. Natl. Acad. Sci. USA. 98:2001;9237-9242.
24. Ahmad-Nejad P., Hacker H., Rutz M., Bauer S., Vabulas R.M., Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32:2002;1958-1968.
25. Hemmi H., Kaisho T., Takeda K., Akira S. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J. Immunol. 170:2003;3059-3064.
26. Hartmann G., Weiner G.J., Krieg A.M. CpG DNA: a potential signal for growth, activation and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA. 96:1999;9305-9310.
27. Gursel M., Verthelyi D., Klinman D.M. CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur. J. Immunol. 32:2002;2617-2622.
28. Krug A., Rothenfusser S., Selinger S., Bock C., Kerkmann M., Battiany J., Sarris A., Giese T., Speiser D., Endres S., Hartmann G. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. J. Immunol. 170:2003;3468-3477.
29. Bohle B., Jahn-Schmid B., Maurer D., Kraft D., Ebner C. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur. J. Immunol. 29:1999;2344-2353.
30. Leifer C.A., Verthelyi D., Klinman D.M. Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides. J. Immunother. 26:2003;313-319.
31. D.M. Klinman, D. Currie, Hierarchical recognition of CpG motifs in immunostimulatory oligodeoxynucleotides. Cell. Immunol., in press, 2003.
32. Lazarus R., Klimecki W.T., Raby B.A., Vercelli D., Palmer L.J., Kwiatkowski D.J., Silverman E.K., Martinez F., Weiss S.T. Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies. Genomics. 81:2003;85-91.
33. Renshaw M., Rockwell J., Engleman C., Gewirtz A., Katz J., Sambhara S. Cutting edge: impaired Toll-like receptor expression and function in aging. J. Immunol. 169:2002;4697-4701.
34. Jones T.R., Obaldia N., Gramzinski R.A., Charoenvit Y., Kolodny N., Kitov S., Davis H.L., Krieg A.M., Hoffman S.L. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenic vaccine in Aotus monkeys. Vaccine. 17:1999;3065-3071.
35. Verthelyi D., Kenney R.T., Seder R.A., Gam A.A., Friedag B., Klinman D.M. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J. Immunol. 168:2002;1659-1663.
36. Verthelyi D., Gursel M., Kenney R.T., Lifson J.D., Shuying L., Mican J., Klinman D.M. CpG oligodeoxynucleotides protect normal and SIV infected macaques from Leishmania infection. J. Immunol. 170:2003;4717-4723.
37. H.L. Davis, I.I. Suparto, R.R. Weeratna, Jumintarto, Iskandriati, S.S. Chamzah, A.A. Ma'ruf, D.D. Nente, A.M. Krieg, Heriyanto, W. Smits, D.D. Sajuthi, CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 19 (2000) 413-422.
38. Lipford G.B., Bauer M., Blank C., Reiter R., Wagner H., Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27:1997;2340-2344.
39. Krieg A.M., Davis H.L. Enhancing vaccines with immune stimulatory CpG DNA. Curr. Opin. Mol. Ther. 3:2001;15-24.
40. A.M. Krieg, Mechanisms and therapeutic applications of immune stimulatory CpG ODN. Sixth NIH Symposium on Therapeutic Oligonucleotides, December 16-17, 2002, Bethesda, MD.
41. L.S. Davis, A.M. Krieg, C.L. Cooper, D.W. Cameron, J. Heathcote, CpG ODN is generally well tolerated and highly effective in humans as adjuvant to HBV vaccine: preliminary results of phase I trial with CpG ODN 7909. 2nd international Symposium "Activating Immunity with CpG Oligos," Amelia Island, FL, October 7-10. 2001.
42. Antunes C.M., Mayrink W., Magalhaes P.A., Costa C.A., Melo M.N., Dias M., Michalick M.S., Williams P., Lima A.O., Vieira J.B. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int. J. Epidemiol. 15:1986;572-580.
43. Nascimento E., Mayrink W., da Costa C.A., Michalick M.S., Melo M.N., Barros G.C., Dias M., Antunes C.M., Lima M.S., Taboada D.C. Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses. Infect. Immun. 58:1990;2198-2203.
44. Zimmermann S., Egeter O., Hausmann S., Lipford G.B., Rocken M., Wagner H., Heeg K. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine Leishmaniasis. J. Immunol. 160:1998;3627-3630.
45. Walker P.S., Scharton-Kersten T., Krieg A.M., Love-Homan L., Rowton E.D., Udey M.C., Vogel J.C. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma- dependent mechanisms. Proc. Natl. Acad. Sci. USA. 96:1999;6970-6975.
46. Walker P.S., Scharton-Kersten T., Krieg A.M., Love-Homan L., Rowton E.D., Udey M.C., Vogel J.C. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12 and IFNg dependent mechanisms. Proc. Natl. Acad. Sci. USA. 96:1999;6970-6975.
47. Pisetsky D.S., Reich C. Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligonucleotides. Mol. Biol. Rep. 18:1993;217-221.
48. Klinman D.M., Conover J., Coban C. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect. Immun. 67:1999;5658-5663.
49. Kenney R.T., Sacks D.L., Sypek J.P., Vilela L., Gam A.A., Evans-Davies K. Protective immunity using recombinant human II-12 and alum a adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol. 163:1999;4481-4488.
50. Olbrich A.R., Schimmer S., Heeg K., Schepers K., Schumacher T.N., Dittmer U. Effective postexposure treatment of retrovirus- induced disease with immunostimulatory DNA containing CpG motifs. J. Virol. 76:2002;11397-11404.
51. Klinman D.M., Verthelyi D., Takeshita F., Ishii K.J. Immune recognition of foreign DNA: a cure for bioterrorism? Immunity. 11:1999;123-129.
52. Horner A.A., Raz E. Immunostimulatory sequence oligodeoxynucleotide- based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases. J. Allergy Clin. Immunol. 110:2002;706-712.
53. Tighe H., Takabayashi K., Schwartz D., Van Nest G., Tuck S., Eiden J.J., Kagey-Sobotka A., Creticos P.S., Lichtenstein L.M., Spiegelberg H.L., Raz E. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 106:2000;124-134.
54. Bohle B. CpG motifs aas possible adjuvants for treatment of allergic diseases. Int. Arch. Allergy Immunol. 129:2002;198-203.
55. Wooldridge J.E., Ballas Z., Krieg A.M., Weiner G.J. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 89:1997;2994-2998.
56. Carpentier A.F., Chen L., Maltonti F., Delattre J.Y. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res. 59:1999;5429-5432.
57. Ballas Z.K., Krieg A.M., Warren T., Rasmussen W., Davis H.L., Waldschmidt M., Weiner G.J. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167:2001;4878-4886.
58. Weiner G.J. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J. leukocyte Biol. 68:2000;455-463.
59. Jahrsdorfer B., Hartmann G., Racila E., Jackson W., Muhlenhoff L., Meinhardt G., Endres S., Link B.K., Krieg A.M., Weiner G.J. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J. Leukocyte Biol. 69:2001;81-88.
60. Decker T., Schneller F., Sparwasser T., Tretter T., Lipford G.B., Wagner H., Peschel C. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood. 95:2000;999-1006.
61. Decker T., Hipp S., Kreitman R.J., Pastan I., Peschel C., Licht T. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood. 99:2002;1320-1326.
62. Warren T.L., Weiner G.J. Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma. Semin. Oncol. 29:2002;93-97.
63. U. Trefzer, C. Kors, K. Pelzer, P. Walden, W. Sterry, E. O'Keefe, Preliminary results from a phase I trial of intralesional injection of CpG ODN in basal cell carcinoma and melanoma. 2nd International Symposium "Activating Immunity with CpG Oligos," Ameila Island, FL, October 7-10, 2001.
64. Press release. Coley pharmaceutical group's CpG 7909 in immunocompromised patients. Bionews Ottawa February, 4-5.2003.
65. Yung R.L., Richardson B.C. Role of T cell DNA methylation in lupus syndromes. Lupus. 3:1994;487-491.
66. Richardson B., Scheinbart L., Strahler J., Gross L., Hanash S., Johnson M. Evidence for impaired T cell DNA methylation in SLE and RA. Arthritis Rheum. 33:1990;1573-1665.
67. Sato Y., Miyata M., Sato Y., Nishimaki T., Kochi H., Kasukawa R. CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro. J. Rheumatol. 26:1999;294-301.
68. Zeuner R.A., Klinman D.M., Illei G., Yarboro C., Ishii K.J., Gursel M., Verthelyi D. Response of peripheral blood mononuclear cells from lupus patients to stimulation by CpG oligodeoxynucleotides. Rheumatology (Oxford). 42:2003;563-569.
69. D. Verthelyi, D.M. Klinman, in: E. Raz (ed), Microbial DNA and Immune modulation, Humana, CA; 2002, pp. 385-396.
70. Deng G.M., Tarkowski A. The features of arthritis induced by CpG motifs in bacterial DNA. Arthritis Rheum. 43:2000;356-364.
71. Obermeier F., Dunger N., Deml L., Herfarth H., Scholmerich J., Falk W. CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. Eur. J. Immunol. 32:2002;2084-2092.
72. Bachmaier K., Meu N., Maza L.M., Pal S., Nessel A., Penninger J.M. Chlamydia infections and heart disease linked through antigenic mimicry. Science. 283:1999;1335-1339.